Joshua Thornsberry
LightNews LightNews
banner
thornsberryjd.bsky.social
Joshua Thornsberry
@thornsberryjd.bsky.social
200 followers 420 following 36 posts
🎓 DNP 🥼 Nurse Practitioner 🫀 Hearts
🏥 APP Fellowship Director 🍎 Educator
🏠 ATL 🏳️‍🌈 LGBTQ+ ⛺️ Camper

#ACC #ACCCVT #CCKE #ACCPRIDE
#AANP #NPsLead #CardioSky #MedSky

DNP, AGACNP-BC, ANP-BC, CCK, AACC
Posts Replies Media Videos
Pinned
thornsberryjd.bsky.social
Joshua Thornsberry @thornsberryjd.bsky.social · Mar 3
🚨 Big News! I’m a #ACC25 Social Media Ambassador! 🚨

🫀 I’ll be live from Chicago, March 29-31 – bringing you exclusive updates from @accintouch.bsky.social and @jaccjournals.bsky.social

Drop a 💙 if you’re attending!

🔗 Learn more: accscientificsession.acc.org

#ACC25 #CardioSky #ACCCVT
Reposted by Joshua Thornsberry
drmonalidesai.bsky.social
An interesting study looking at using a deep learning model to evaluate ECGs in the emergency room to determine if patients need coronary revascularization as existing methods can sometimes be inconclusive.
academic.oup.com/eurheartj/ad...
April 5, 2025 at 12:53 PM
thornsberryjd.bsky.social
Tomorrow is your last chance to visit this BP measurement learning station at #ACC25!

Avoiding common pitfalls is key to accurate care—don’t miss it in the Personalized Skills Center.

learn.acc.org/Page/LEARNHTN

#ACCCVT #CardioSky #WellstarCVteam

@accintouch.bsky.social @jaccjournals.bsky.social
March 30, 2025 at 10:11 PM
Reposted by Joshua Thornsberry
accintouch.bsky.social
ALPACA: The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of Lp(a) from 60 to 180 days after being administered subcutaneously. #ACC25

Learn more about the study ➡️ bit.ly/3Y1DkU7

#CardioSky #MedSky
March 30, 2025 at 8:25 PM
Reposted by Joshua Thornsberry
jaccjournals.bsky.social
Dr. Victor Dzau presenting his keynote speech, Science, Medicine, and Society: A Brave New World, during the 2025 Eugene Braunwald Keynote happening now! 📍Room S100b

#ACC25 #CardioSky
March 30, 2025 at 8:40 PM
Reposted by Joshua Thornsberry
nephroseeker.medsky.social
FRESH-UP Trial #ACC25 #medsky

RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF

🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction

www.nature.com/articles/s41...
March 30, 2025 at 8:50 PM
Reposted by Joshua Thornsberry
drbenzigerheart.bsky.social
Dr. Victor Dzau:
How do we improve #cvd with rising #obesity?
✅Start with 1° and 2° #cvprev
✅Primordial prevention

@accintouch.bsky.social #acc25
March 30, 2025 at 9:11 PM
Reposted by Joshua Thornsberry
drbenzigerheart.bsky.social
Dr. Victor Dzau:
Future of #CVD care is going to be evolving rapidly over the next century:
❤️ Emphasis on prevention
❤️ Equitable access and affordable
❤️ Mission-based innovation
❤️ Develop national priorities

Need governance to oversee innovation, ensure ethics

#acc25
@accintouch.bsky.social
March 30, 2025 at 9:24 PM
thornsberryjd.bsky.social
Wellstar team-based care in action at #ACC25!

This poster showcases a coordinated strategy to improve SGLT2i use post-AMI—driving better prescribing, education, and follow-up for patients.

#ACCCVT #CardioSky #WellstarCVteam

@accintouch.bsky.social @jaccjournals.bsky.social
March 30, 2025 at 9:44 PM
thornsberryjd.bsky.social
FRESH-UP at #ACC25: No benefit to fluid restriction in HF. No harm with liberal intake. Improved QOL with more fluid freedom.

Supports what we have long suspected—and may help shift the standard of care moving forward.

#CardioSky #WellstarCVteam

@accintouch.bsky.social @jaccjournals.bsky.social
accintouch.bsky.social American College of Cardiology @accintouch.bsky.social · Mar 30
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25.

Check out the key findings ➡️ bit.ly/3DYGHEl

#CardioSky #MedSky
March 30, 2025 at 9:36 PM
Reposted by Joshua Thornsberry
jaepattonnp.bsky.social
#ACC25 #LGBTQ work group represents at the Health #Equity Hub!

Dr Deb and Dr Coylewright - So proud of the work you’re both doing!

@thornsberryjd.bsky.social
@brototod.bsky.social
March 30, 2025 at 4:37 PM
Reposted by Joshua Thornsberry
jaepattonnp.bsky.social
Join us for this exciting session on management of CIEDs in complex patients -
#ACC25 #CIED #cardiopalli #SDM
@accintouch.bsky.social @thornsberryjd.bsky.social
March 30, 2025 at 6:19 PM
thornsberryjd.bsky.social
EquiOx at #ACC25 confirms it: pulse oximeters don’t perform equally across skin tones—especially critically ill patients

Wellstar’s, Dr. Paul Douglass shared insight on the need for equity in device validation

#ACCCVT #CardioSky #WellstarCVteam

@accintouch.bsky.social @jaccjournals.bsky.social
March 30, 2025 at 3:17 PM
thornsberryjd.bsky.social
MIGHTy-Heart took on gaps in HF care transitions.

✴️ 2,003 enrolled → MIH vs. TOCC
✴️ No difference in 30-day outcomes
✴️ Younger patients & women saw more benefit.

Impressive representation: 52% women, 47% Black

#ACC25 #CardioSky #WellstarCVteam

@accintouch.bsky.social @jaccjournals.bsky.social
March 30, 2025 at 3:12 PM
Reposted by Joshua Thornsberry
katiekalvaitis.bsky.social
🔥Hot off the press:

Highlights from day 1 at #ACC25 #CardioSky

📌 WARRIOR
📌 STRIDE
📌 API-CAT
📌 SOUL
📌 RIVAWAR
📌 & more in the link

www.healio.com/news/cardiol...
https://healio.com/news/cardiolog…
March 30, 2025 at 12:08 AM
Reposted by Joshua Thornsberry
sjenkinsmd.bsky.social
Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo #MedSky #CardioSky #NephSky
www.nejm.org/doi/full/10....
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes | NEJM
The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ca...
www.nejm.org
March 30, 2025 at 12:09 AM
Reposted by Joshua Thornsberry
katiekalvaitis.bsky.social
More from day 1 #ACC25 …

📌 WARRIOR = the largest study of women with suspected ischemia with nonobstructive coronary disease

📌 Intensive medical therapy did not prevent 🫀 events for women with INOCA

📌 “This trial should not be considered a negative trial”

www.healio.com/news/cardiol...
Intensive medical therapy does not help or harm women with chest pain: WARRIOR
CHICAGO — Among women with suspected ischemia with nonobstructive coronary disease, an intensive medical therapy strategy did not reduce risk for major adverse CV events at 5 years compared with...
www.healio.com
March 30, 2025 at 12:13 AM
Reposted by Joshua Thornsberry
jaepattonnp.bsky.social
#ACC25 #Palliative Workgroup Huddle!

So much creativity and compassion - and WORK - in the this group!

#ACCGeriatric #ACCFIT #ACCCVT
@accintouch.bsky.social @shummelmd.bsky.social @thornsberryjd.bsky.social
March 29, 2025 at 11:22 PM
Reposted by Joshua Thornsberry
cardioobdoc.bsky.social
Join us for a fun #CardioObstetrics session at #ACC25 #CardioSky

📅 Sun, Mar 30
⏰ 10AM

@accintouch.bsky.social @mdharringtonc.bsky.social @drklindley.bsky.social @abraguo.bsky.social @garimasharmamd.bsky.social @drmarthagulati.bsky.social @erinmichos.bsky.social @thornsberryjd.bsky.social
March 29, 2025 at 11:10 PM
Reposted by Joshua Thornsberry
cardioobdoc.bsky.social
Join us now for #ACC25 #CardioObstetrics Meet-Up
@accintouch.bsky.social @mdharringtonc.bsky.social @drklindley.bsky.social
March 29, 2025 at 9:49 PM
Reposted by Joshua Thornsberry
cardioobdoc.bsky.social
Today at 4:30PM
Don’t miss #ACC25 #CardioObstetrics Meet-Up
abraguo.bsky.social Abra Guo, MD @abraguo.bsky.social · Mar 24
T minus 5 days to #ACC25 🚨🚨🚨
🫀Reprohealth and #Cardioobstetrics member Meet-Up
🫀When: March 29 4:30 CST
🫀Where: Lounge + Learn Pavilion. Zone 2

#cardiosky #medsky #obsky #maternalhealth #reprosky #highriskpregnancy #mfmsky
#womensheartdisease @accintouch.bsky.social @acog-org.bsky.social
March 29, 2025 at 3:30 PM
thornsberryjd.bsky.social
📆 Mark your calendars for Monday at #ACC25!

Wellstar MCG presents a high-stakes case: RotaWire entrapment, fracture, and retrieval—titled “When It Rains It Pours.” ☔️💙

You won’t want to miss this one!

#WellstarCVteam #CardioSky

@accintouch.bsky.social @jaccjournals.bsky.social
March 29, 2025 at 11:01 PM
Reposted by Joshua Thornsberry
accintouch.bsky.social
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25

Read the journal scan to learn more: bit.ly/3QTpizK

#CardioSky #MedSky
March 29, 2025 at 10:01 PM
Reposted by Joshua Thornsberry
accintouch.bsky.social
DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25

More: bit.ly/4cfLNsy

#cvSurg #CardioSky #MedSky
March 29, 2025 at 10:22 PM
Reposted by Joshua Thornsberry
brendonneuen.bsky.social
In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date)

The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use

#ACC25

www.ahajournals.org/doi/abs/10.1...
March 29, 2025 at 10:25 PM